Resource Library Search

Resource Library Search Filter

Filter By Resource Library: Format Type

Journal Article (50)

Podcast (4)

Consensus Recommendations (2)

Filter By Resource Library: Topic

Timing of MRD Testing (56)

Learn (54)

Lay the Groundwork (44)

Prepare the Care Team (41)

MRD Testing Methods (37)

Treatment Decision-Making (27)

Multiple Myeloma (24)

Clinical Trials (20)

B-cell ALL (18)

Treatment (12)

Implement the Initiative (10)

Assess (8)

CLL (8)

Resource Library Search

You searched for:

Timing of MRD Testing

Displaying results 41 - 56 of 56

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions

This comprehensive review focuses on the recent advances and future directions in novel therapeutic strategies in adult ALL.

Journal of Hematology & Oncology

B-cell ALL Learn Prepare the Care Team Timing of MRD Testing Treatment Treatment Decision-Making Journal Article

Role of imaging in the evaluation of minimal residual disease in multiple myeloma patients

Brief review of imaging-based sensitive response assessment through the use of functional rather than morphological whole-body imaging techniques, such as positron emission tomography with computed tomography and magnetic resonance imaging, as a strategy to overcome limitations of flow-cytometry or molecular-based methods, such as the patchy infiltration of bone marrow plasma cells and the presence of extra-medullary, in evaluating response to therapy and in the assessment of the MRD status in MM patients.

Journal of Clinical Medicine

Lay the Groundwork Learn MRD Testing Methods Multiple Myeloma Prepare the Care Team Timing of MRD Testing Journal Article

Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis

Minimal residual disease (MRD) refers to the presence of disease in cases deemed to be in complete remission by conventional pathologic analysis. Assessing the association of MRD status following induction therapy in patients with ALL with relapse and mortality may improve the efficiency of clinical trials and accelerate drug development.

JAMA Oncology

B-cell ALL Lay the Groundwork Learn Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Minimal residual disease in multiple myeloma: are we there yet?

Brief review article that concludes, "With the approval of several new drugs with different mechanisms of action and the incorporation of MRD as an end-point in clinical trials, the management landscape of MM is changing rapidly. Given the significant impact of MRD negativity on the outcomes, it could be a new regulatory surrogate end-point for survival in clinical trials and a main driver of research and clinical practice in MM in the future.

International Journal of Hematologic Oncology

Clinical Trials Lay the Groundwork Learn Multiple Myeloma Prepare the Care Team Timing of MRD Testing Treatment Treatment Decision-Making Journal Article

Should undetectable minimal residual disease be the goal of chronic lymphocytic leukemia therapy?

This review discusses available methods of minimal residual disease measurement. It summarizes minimal residual disease data from pivotal clinical trials and discusses potential implications for future studies and minimal residual disease-based clinical strategies.

Hematology/Oncology Clinics of North America

Clinical Trials CLL Lay the Groundwork Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Journal Article

Minimal residual disease in multiple myeloma: why, when, where

We review the data supporting MRD testing as well as its limitations and how it may fit in with current and future clinical practice.

Hematology

Assess Implement the Initiative Learn Multiple Myeloma Prepare the Care Team Timing of MRD Testing Journal Article

A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia

A systematic literature review and meta-analysis were performed to elucidate the clinical significance of minimal residual disease with respect to relapse-free survival and overall survival in precursor B-cell ALL.

Haematologica

B-cell ALL Lay the Groundwork Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches

This review summarizes current data on MRD in the clinical management of MM, highlights open issues and discusses the challenges and the endless opportunities arising for both patients and clinicians. Furthermore, it focuses on the current status of MRD in clinical trials, its dynamics in addressing debatable aspects in the clinical handling and its potential role as the prevailing factor for future MRD-driven tailored therapies.

Frontiers in Oncology

Clinical Trials Lay the Groundwork Learn Multiple Myeloma Prepare the Care Team Timing of MRD Testing Treatment Journal Article

Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances

Through a review of the literature and in house data, authors analyze the current status of MRD assessment in ALL to better understand how some of its limitations could be overcome by emerging molecular technologies. Authors highlight the future role of MRD monitoring in the context of personalized protocols, taking into account the genetic complexity in ALL.

Frontiers in Oncology

B-cell ALL Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia

"This monograph examines clinical trial data regarding the role of MRD in CLL, and provides recommendations on how to incorporate MRD assessment into clinical management."

Clinical Advances in Hematology & Oncology

Assess Clinical Trials CLL Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma

We explore the important role of the clinical value of MRD use in the real-world practice in MM. We address new topics in the field of MRDs, including the importance of MRD dynamics and prediction of relapse.

Blood Advances

Implement the Initiative Lay the Groundwork Learn Multiple Myeloma Prepare the Care Team Timing of MRD Testing Journal Article

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

Although levels of minimal residual disease (MRD) decrease below the detection limit in most adult patients with standard-risk ALL after consolidation treatment, about 30% of these patients will ultimately relapse. To evaluate the power of MRD monitoring as an indicator of impending relapse, we prospectively analyzed postconsolidation samples of 105 patients enrolled in the GMALL trial by real-time quantitative polymerase chain reaction (PCR) of clonal immune gene rearrangements.

Blood

B-cell ALL Clinical Trials Lay the Groundwork Learn MRD Testing Methods Timing of MRD Testing Journal Article

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value

Early response to therapy is one of the most important prognostic factors in acute leukemia, which prompted authors to investigate whether or not early immunophenotypic assessment of MRD could also be a valuable tool for predicting relapse in adult patients with ALL. For that purpose, this study analyzed the level of MRD during the initial phase of treatment (induction phase) by multiparameter flow cytometry in a series of 102 adolescent (older than 14 years) and adult patients with ALL.

Blood

B-cell ALL Clinical Trials Lay the Groundwork Learn MRD Testing Methods Timing of MRD Testing Journal Article

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

To identify complementary markers suitable for further treatment stratification in SR ALL, the study evaluated the predictive value of MRD and prospectively monitored MRD in 196 strictly defined SR ALL patients at up to 9 time points in the first year of treatment by quantitative polymerase chain reaction (PCR).

Blood

B-cell ALL Lay the Groundwork Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Journal Article

Minimal residual disease in multiple myeloma: current status

In this review article, we outlined the major clinical trials that have determined the prognostic value of MRD in MM. We also reviewed different methods that were used for MM MRD assessment. Most important, we reviewed our current understanding of MM MRD biology.

Biomarker Research

Clinical Trials Lay the Groundwork Learn MRD Testing Methods Multiple Myeloma Prepare the Care Team Timing of MRD Testing Journal Article

International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion�based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.

Blood

CLL Lay the Groundwork Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Consensus Recommendations

Displaying results 41 - 56 of 56

Share

In This Section

Resource Library Search Filter

Resource Library Search

Share

In This Section

Resource Library Search Filter

Resource Library Search

Sharing Article: